Patent application number | Description | Published |
20100143926 | Classification of Patients Having Diffuse Large B-cell Lymphoma Based upon Gene Expression - Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival. | 06-10-2010 |
20100183655 | Immunogenic Protein Constructs - Bacterial immunity proteins are utilized to increase immune response to an antigen of interest. | 07-22-2010 |
20110129438 | IMMUNOGENIC PROTEIN CONSTRUCTS - Bacterial immunity proteins are utilized to increase immune response to an antigen of interest. | 06-02-2011 |
20120134986 | Methods of Prognosis for Non-Hodgkin Lymphoma - Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis. | 05-31-2012 |
20120321646 | Methods for Enhancing Anti-Tumor Antibody Therapy - Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule. | 12-20-2012 |
20140220562 | Method of Predicting Responsiveness of B Cell Lineage Malignancies to Active Immunotherapy - Predictive biomarkers identify those patients suffering from immunoglobulin positive (Ig | 08-07-2014 |
20150118222 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY - Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with immunotherapy are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and an immune checkpoint inhibitor. | 04-30-2015 |
20150315660 | METHODS AND COMPOSITIONS FOR DETERMINING RESPONSIVENESS TO ANTIBODY THERAPY - Methods and compositions are provided for determining whether a subject suffering from a neoplastic condition is responsive to an antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, the subject is genotyped to determine whether the subject has a least one favorable FcγR polymorphism, e.g., the131 H/H genotype or the158 VN genotype. In addition, reagents, devices and kits thereof, that find use in practicing the subject methods are provided. | 11-05-2015 |